Among critically ill adults with metabolic acidosis receiving vasopressors in the ICU, sodium bicarbonate did not lead to a lower risk of major adverse kidney events within 30 days than placebo.
Author: The SODa-BIC Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group
Posted: June 12, 2026, 12:00 am
Among adults with septic shock, the use of restricted fluids and early vasopressors did not result in more days alive and out of the hospital through day 90 than the use of liberal fluids and later vasopressors.
Author: The ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network
Posted: June 11, 2026, 12:00 am
The authors review current strategies for anticoagulation reversal in major bleeding events or urgent surgery as well as specific antidotes, limits of available evidence, thrombotic risks, unmet therapeutic needs, and ongoing research.
Author: Bianca Rocca, Hugo ten Cate
Posted: June 11, 2026, 12:00 am
Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,...
Author: Michael F. Murphy, Ian Roberts
Posted: June 10, 2026, 12:00 am
In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days.
Author: Brett L. Houston, Daniel I. McIsaac, Rodney H. Breau, Salmaan Kanji, Peter Greenstreet, Meghan Andrews, Sinziana Avramescu, Hema S. Bagry, Robert Balshaw, Jayesh Daya, Kaitlin Duncan, Christopher C. Harle, Eric Jacobsohn, Tina Kerelska, Marshall Pitz, Paul Komenda, Sarah McIsaac, Tim Ramsay, Tarit Saha, Alan Tinmouth, Angela Recio, Daniel Szoke, Marshall Tenenbein, Sarah Slagerman, Dayna Solvason, Robert Talarico, Dean A. Fergusson, Ryan Zarychanski
Posted: June 10, 2026, 12:00 am
Among critically ill adults with acute respiratory failure, neither carbocisteine nor hypertonic saline reduced the duration of mechanical ventilation, and each strategy was associated with harm.
Author: Bronwen Connolly, Naomi Dickson, Christina Campbell, Judy M. Bradley, Brenda O’Neill, Ashley Agus, Mike Barker, Jeremy S. Bewley, Bronagh Blackwood, Mark Borthwick, Luigi Camporota, Marc Chikhani, Mike Clarke, Paul Dark, Lisa Higgins, Penelope Lambert, Thomas Lunn, Cliona McDowell, Margaret McFarland, Una McShane, Reena Mehta, Ben Messer, Ben Morton, Nehal Patel, Gavin D. Perkins, Deborah Rowley, Murali Shyamsundar, Jonathan A. Silversides, Gordon Sturmey, John Warburton, Barry Williams, Ranjit Lall, Daniel F. McAuley, the MARCH Trial Investigators*
Posted: June 10, 2026, 12:00 am
Among patients who were unresponsive after cardiac arrest, conservative oxygen therapy did not increase 180-day survival with favorable function as compared with liberal oxygen therapy.
Author: The LOGICAL Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group
Posted: June 10, 2026, 12:00 am
Acute hypoxemic respiratory failure remains one of the most common conditions encountered in the intensive care unit (ICU).1 During the past decade, high-flow nasal oxygen has moved from physiological curiosity to frontline therapy.2 Early enthusiasm followed the publication of the results of the 2015 FLORALI trial,
Author: Ary Serpa Neto
Posted: June 4, 2026, 12:00 am
In a multicenter trial involving patients with acute hypoxemic respiratory failure, 28-day mortality with high-flow oxygen was not significantly different from that with standard oxygen.
Author: Jean-Pierre Frat, Jean-Pierre Quenot, Christophe Guitton, Rémi Coudroy, Arnaud Gacouin, Julio Badie, Alexandre Demoule, Damien Contou, Guillaume Carteaux, Stephan Ehrmann, Fabien Jarousseau, Nicholas Sedillot, Jean-Philippe Rigaud, Jean Reignier, François Beloncle, Anne-Florence Dureau, Alexis Ferré, Cédric Daubin, Anna Bourreau, Agathe Delbove, Gaël Pradel, Abdelhamid Fatah, Gwenhael Colin, Guillaume Deniel, Olivier Lamouret, Béatrice La Combe, Gwénaël Prat, Louis-Marie Galerneau, Gaël Bourdin, Gautier Julien, Anaïs Curtiaud, Mélanie Saint-Léger, Emanuele Turbil, Faustine Reynaud, Louis Chamblet, Stéphanie Ragot, Arnaud W. Thille, the SOHO Trial Group and the REVA Network*
Posted: June 4, 2026, 12:00 am
IgG4-related disease has emerged as one of the clearest human models for understanding the role of B-lineage cells in immune-mediated inflammation. Although glucocorticoids remain effective for inducing remission, relapse during tapering is common, cumulative toxic effects are substantial, and durable disease control remains difficult to achieve. Della-Torre et al.1
Author: Thomas Dörner
Posted: June 2, 2026, 12:00 am